CARDIFF ONCOLOGY INC

CRDF represents the common stock of Cardiff Oncology, Inc., a clinical-stage biotechnology company. The ticker trades on the Nasdaq Capital Market. As a stock, CRDF gives investors an ownership interest in the company, whose value is tied to its pipeline progress, clinical trial outcomes, and financial position. Because it is a development-stage biotech, its stock often reacts to news about drug candidates rather than commercial sales.

Recent performance for CRDF depends on the latest trading session and market activity. For the most current price change, percentage move, and volume, check the live quote and performance chart on this page. These figures update throughout the trading day. Rather than relying on stale data, review the latest CRDF price and daily range displayed here before drawing conclusions.

Determining whether CRDF is overvalued or undervalued is not straightforward because clinical-stage biotechs often have no product revenue, making traditional metrics like the P/E ratio inapplicable. Valuation may instead reflect cash reserves, pipeline potential, trial readouts, and financing needs. The latest CRDF market data and any disclosed financials on this page can help frame that assessment.

CRDF may be available for trading in pre-market and after-hours sessions through certain brokers, though liquidity and spreads can differ significantly from regular hours. Extended-hours trading carries additional risks, including wider price swings and lower volume. Not all brokers or order types support it. Check with your brokerage and review the latest CRDF quote to see available session data.

CRDF does not currently pay dividends. Cardiff Oncology is a clinical-stage biotech that typically reinvests capital into research and development rather than returning cash to shareholders. Any future dividend decision would depend on factors such as profitability, cash position, and corporate strategy. For the latest dividend status, refer to the distribution information shown on this page.

Key risks for CRDF include clinical trial failure, regulatory setbacks, reliance on external financing, and potential dilution from future capital raises. As a small-cap biotech, its share price can be volatile and sensitive to pipeline news. Competition, intellectual property challenges, and general market conditions may also affect results. Review CRDF's risk disclosures and financial statements for a fuller picture.